Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This is an investigation of minocycline efficacy and safety as an adjuvant to risperidone in management of children with autism. METHODS: Forty-six children with diagnosis of autistic disorder, according to the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria and a score of ≥12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale, who were already drug-free for at least 6 months participated in a randomized controlled trial and underwent 10 weeks of treatment with either minocycline (50 mg twice per day) or placebo in addition to risperidone titrated up to 2 mg/day (based on bodyweight). Patients were evaluated using ABC-C at baseline and at weeks 5 and 10. RESULTS: General linear model repeated measures showed significant effect for time × treatment interaction on the irritability [F(2, 88) = 3.94, p = 0.02] and hyperactivity/noncompliance [F(1.50, 66.05) = 7.92, p = 0.002], but not for lethargy/social withdrawal [F(1.61, 71.02) = 0.98, p = 0.36], stereotypic behavior [F(1.34, 58.80) = 1.55, p = 0.22], and inappropriate speech subscale scores [F(1.52, 66.88) = 1.15, p = 0.31]. By week 10, 21 (91.3%) patients in the minocycline group and 15 (65.5%) patients in the placebo group achieved at least partial response (p = 0.03). Frequencies of adverse events were not significantly different between groups. CONCLUSIONS: Minocycline seems to be a safe and effective adjuvant in management of patients with autistic disorder. Future studies with larger sample sizes, longer follow-ups, and inflammatory cytokine measurements are warranted to confirm these findings and provide insight into minocycline mechanism of action in autistic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of Autism and Other Pervasive Developmental Disorders
Elsabbagh, M., Divan, G., Koh, Y., Kim, Y. S., Kauchali, S., Marcín, C., Montiel‐Nava, C., Patel, V., Paula, C. S., Wang, C., et al. (2012) · Autism Research · doi:10.1002/aur.239 · Cited by 2,636
Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations
O’Roak, B. J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B. P., Levy, R., Ko, A., Lee, C., Smith, J. D., et al. (2012) · Nature · doi:10.1038/nature10989 · Cited by 2,165 · cited 1×
“Several mutations in genes encoding subunits of NMDA receptors, mostly de novo , have been reported in patients with ASD (O’Roak et al. 2012a, 2012b; Kenny et al. 2014), which are suspected to alter the function of these receptors and NMDA receptor-dependent plasticity (Lee et al. 2015).”
Neuroglial activation and neuroinflammation in the brain of patients with autism
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005) · Annals of Neurology · doi:10.1002/ana.20315 · Cited by 2,149 · cited 2×
“…G and M (Heuer et al. 2008) in the presence of immunoglobulin G autoantibodies against neuron-axon filament and glial fibrillary acidic proteins (Singh et al. 1997), and increased micro-glial and astrocytic density and activation (Vargas et al. 2005; Morgan et al. 2010) have been documented.”
Multiplex Targeted Sequencing Identifies Recurrently Mutated Genes in Autism Spectrum Disorders
O’Roak, B. J., Vives, L., Fu, W., Egertson, J. D., Stanaway, I. B., Phelps, I. G., Carvill, G., Kumar, A., Lee, C., Ankenman, K., et al. (2012) · Science · doi:10.1126/science.1227764 · Cited by 1,240
Ashwood, P., Krakowiak, P., Hertz-Picciotto, I., Hansen, R., Pessah, I., & Van de Water, J. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.08.003 · Cited by 940 · cited 2×
“…of T helper cells (Gupta et al. 1998), increased plasma levels of proinflammatory cytokines such as interleukin 1, 6, and 8 (Jyonouchi et al. 2001; Ashwood et al. 2011), increased proliferation and activation of B cells and natural killer cells (Ashwood et al. 2011), decreased serum levels of…”
Morgan, J. T., Chana, G., Pardo, C. A., Achim, C., Semendeferi, K., Buckwalter, J., Courchesne, E., & Everall, I. P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.024 · Cited by 749
Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 1×
“Interestingly, both animal studies on the FXS rat model (Bilousova et al. 2009) and clinical trials on patients with FXS have shown minocycline to be effective and safe in improving behavioral function (Paribello et al. 2010; Leigh et al. 2013).”
Hansen, S. N., Schendel, D. E., & Parner, E. T. (2015) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2014.1893 · Cited by 461 · cited 1×
“Global prevalence of ASDs is now estimated to be about 62 per 10,000 population (Elsabbagh et al. 2012) with a significant increase in recent decades mainly due to changes in the number of reported cases (Hansen et al. 2015).”
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453 · cited 2×
“…such as depression (Miyaoka et al. 2012), schizophrenia (Miyaoka et al. 2008; Khodaie-Ardakani et al. 2014), and Parkinson’s disease (NINDS NET-PD Investigators 2006, 2008), as well as animal models of Huntington’s disease (Chen et al. 2000) and amyotrophic lateral sclerosis (Zhang et al. 2003).”
Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298 · cited 1×
“Interestingly, both animal studies on the FXS rat model (Bilousova et al. 2009) and clinical trials on patients with FXS have shown minocycline to be effective and safe in improving behavioral function (Paribello et al. 2010; Leigh et al. 2013).”
Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism
Gupta, S., Aggarwal, S., Rashanravan, B., & Lee, T. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00021-6 · Cited by 250 · cited 2×
“Another suspected mechanism in the etiopathogenesis of ASD (Gupta et al. 1998) is based on the fact that a decreased serum level of MMP-9 is also reported to inhibit the activation and migration of T helper cells to the brain (Brundula et al. 2002).”
Circulating autoantibodies to neuronal and glial filament proteins in autism
Singh, V. K., Warren, R., Averett, R., & Ghaziuddin, M. (1997) · Pediatric Neurology · doi:10.1016/s0887-8994(97)00045-3 · Cited by 234
Open-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 1×
“Interestingly, both animal studies on the FXS rat model (Bilousova et al. 2009) and clinical trials on patients with FXS have shown minocycline to be effective and safe in improving behavioral function (Paribello et al. 2010; Leigh et al. 2013).”
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.002 · Cited by 212
NMDA receptor dysfunction in autism spectrum disorders
Lee, E.-J., Choi, S. Y., & Kim, E. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.10.007 · Cited by 192
Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms
Heuer, L., Ashwood, P., Schauer, J., Goines, P., Krakowiak, P., Hertz‐Picciotto, I., Hansen, R., Croen, L. A., Pessah, I. N., & Van de Water, J. (2008) · Autism Research · doi:10.1002/aur.42 · Cited by 190 · cited 1×
“…increased proliferation and activation of B cells and natural killer cells (Ashwood et al. 2011), decreased serum levels of immunoglobulin G and M (Heuer et al. 2008) in the presence of immunoglobulin G autoantibodies against neuron-axon filament and glial fibrillary acidic proteins (Singh et al.…”
Fragile X: Leading the Way for Targeted Treatments in Autism
Wang, L. W., Berry-Kravis, E., & Hagerman, R. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.005 · Cited by 176
High MMP-9 activity levels in fragile X syndrome are lowered by minocycline
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin‐Johnson, B., Hagerman, R. J., & Tassone, F. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36023 · Cited by 161 · cited 1×
“Furthermore, minocycline has been shown to decrease MMP-9 levels, particularly in FXS, a disorder with presumed mechanistic similarities with ASD, which was also accompanied by improvements in symptoms of disease in some cases (Dziembowska et al. 2013).”
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146 · cited 1×
“Minocycline has shown promising results in patients with several psychological disorders such as depression (Miyaoka et al. 2012), schizophrenia (Miyaoka et al. 2008; Khodaie-Ardakani et al. 2014), and Parkinson’s disease (NINDS NET-PD Investigators 2006, 2008), as well as animal models of…”
Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.051 · Cited by 104 · cited 1×
“…promising results in patients with several psychological disorders such as depression (Miyaoka et al. 2012), schizophrenia (Miyaoka et al. 2008; Khodaie-Ardakani et al. 2014), and Parkinson’s disease (NINDS NET-PD Investigators 2006, 2008), as well as animal models of Huntington’s disease…”
Self-citationTreatment of inattention, overactivity, and impulsiveness in autism spectrum disorders
Aman, M. G., Farmer, C. A., Hollway, J., & Arnold, L. E. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.06.009 · Cited by 82
A pilot open-label trial of minocycline in patients with autism and regressive features
Pardo, C. A., Buckley, A., Thurm, A., Lee, L.-C., Azhagiri, A., Neville, D. M., & Swedo, S. E. (2013) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-5-9 · Cited by 58
Cited by
Immunoneuropsychiatry — novel perspectives on brain disorders
Pape, K., Tamouza, R., Leboyer, M., & Zipp, F. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0174-4 · Cited by 458
Bordeleau, M., Carrier, M., Luheshi, G. N., & Tremblay, M.-È. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.06.001 · Cited by 75
Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018) · Neuroimmunomodulation · doi:10.1159/000492225 · Cited by 70
On Behalf of the ISACA Guideline Working Group, D’Alò, G. L., De Crescenzo, F., Amato, L., Cruciani, F., Davoli, M., Fulceri, F., Minozzi, S., Mitrova, Z., Morgano, G. P., et al. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01669-0 · Cited by 54
Between Dysbiosis, Maternal Immune Activation and Autism: Is There a Common Pathway?
Suprunowicz, M., Tomaszek, N., Urbaniak, A., Zackiewicz, K., Modzelewski, S., & Waszkiewicz, N. (2024) · Nutrients · doi:10.3390/nu16040549 · Cited by 44
“Due to the immunomodulatory and anti-inflammatory characteristics of minocycline, it is hypothesized to be an adjunctive treatment to risperidone in children with ASD [293].”
Background
Metadata
- Authors
- Ghaleiha, A., Alikhani, R., Kazemi, M.-R., Mohammadi, M.-R., Mohammadinejad, P., Zeinoddini, A., Hamedi, M., Shahriari, M., Keshavarzi, Z., & Akhondzadeh, S.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-11
- Volume
- 26
- Issue
- 9
- Pages
- 784-791
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2342663112
- Cited by
- 55
- References
- 22
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.